Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors

Abstract Background Biomarkers for distinguishing psoriatic arthritis (PsA) from psoriasis without arthritis (PsO) are still lacking. Methods We applied isobaric tags for relative and absolute quantification (iTRAQ) and LC–MS/MS to analyze the proteome profile of peripheral blood mononuclear cells (PBMCs) collected from patients with PsO, patients with PsA, and healthy controls. Bioinformatics analysis and western blotting were performed to identify and validate differentially expressed proteins. Results We identified 389, 199, 291, and 60 significantly differentially expressed proteins (adj.p < 0.05) in the comparison of all psoriatic patients versus healthy controls, PsO group versus healthy controls, PsA group versus healthy controls, and PsA group versus PsO group, respectively. Among these proteins, 14 proteins may represent promising biomarkers for PsA: SIRT2, NAA50, ARF6, ADPRHL2, SF3B6, SH3KBP1, UBA3, SCP2, RPS5, NUDT5, NCBP1, SYNE1, NDUFB7, HTATSF1. Furthermore, western blotting confirmed that SIRT2 expression was significantly higher in PBMCs from PsA patients than PsO and healthy controls, and was negatively correlated with the phosphorylation of p38 mitogen-activated protein kinase (p-p38MAPK; p = 0.006, r = − 0.582). Conclusions This pilot study provided a broad characterization of the proteome of PBMCs in PsA as compared to PsO and healthy controls, which may help to provide prospective strategies for PsA diagnosis.

Download Full-text

The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis – preliminary report

Archives of Medical Science ◽

10.5114/aoms/113027 ◽

2021 ◽

Author(s):

Agata Krawczyk ◽

Barbara Strzałka-Mrozik ◽

Dominika Wcisło-Dziadecka ◽

Magdalena Kimsa-Dudek ◽

Celina Kruszniewska-Rajsa ◽

...

Keyword(s):

Gene Expression ◽

Psoriatic Arthritis ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Mononuclear Cells ◽

Control Group ◽

Systemic Effects ◽

Peripheral Blood Mononuclear ◽

Adalimumab Therapy ◽

Blood Mononuclear Cells

IntroductionThe primary goal of psoriasis treatment is to reduce the inflammatory response and associated complications. In severe cases of psoriasis that are resistant to local treatment (e.g., keratolytic preparations) and at least two types of general treatment methods (e.g., retinoids and cyclosporine A), biological therapy is used. This study aimed to assess the systemic effects of adalimumab at a given stage of treatment in patients with psoriatic arthritis and evaluate how the drug can improve the clinical condition of the patients.Material and methodsThe study group consisted of patients with diagnosed psoriatic arthritis, while the control group consisted of individuals from whom peripheral blood mononuclear cells were obtained. The effects of the administration of adalimumab were assessed by analyzing the gene expression using oligonucleotide microarrays.ResultsThe apoptosis process was indicated as one of the overrepresented categories (the PANTHER classification system 13.1 program, overrepresentativity test, p < 0.05). The dermatological indexes decreased, indicating an improvement in the clinical conditions of the patients three months after the first dose of adalimumab.ConclusionsWe found that adalimumab affects apoptosis, which is crucial in the development and course of psoriasis. The differential gene expression in peripheral blood mononuclear cells of patients with psoriatic arthritis indicated the potential systemic effects of adalimumab therapy. The analyses of dermatological (the Psoriasis Area And Severity Index, body surface area and Dermatology Life Quality Index) and inflammatory (Biernacki’s reaction) parameters revealed the effectiveness of the therapy.

Download Full-text

Differential expression of interleukin-2 by anti-CD3-stimulated peripheral blood mononuclear cells in patients with psoriatic arthritis and patients with cutaneous psoriasis

Clinical and Experimental Dermatology ◽

10.1111/ced.12251 ◽

2013 ◽

Vol 39 (3) ◽

pp. 385-390 ◽

Cited By ~ 6

Author(s):

F. Bosè ◽

F. Capsoni ◽

S. Molteni ◽

L. Raeli ◽

M. Diani ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Differential Expression ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Mononuclear Cells ◽

Interleukin 2 ◽

Peripheral Blood Mononuclear ◽

Blood Mononuclear Cells

Download Full-text

Adenosine A2AReceptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment

International Journal of Alzheimer s Disease ◽

10.4061/2011/484021 ◽

2011 ◽

Vol 2011 ◽

pp. 1-6 ◽

Cited By ~ 1

Author(s):

Beatrice Arosio ◽

Luigina Mastronardi ◽

Cristina Gussago ◽

Paola Nicolini ◽

Alessandra Casè ◽

...

Keyword(s):

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Mononuclear Cells ◽

Cognitive Domain ◽

Genetic Profile ◽

Mrna Levels ◽

Peripheral Blood Mononuclear ◽

Blood Mononuclear Cells

Adenosine suppresses immune responses through the A2Areceptor (A2AR). This study investigated the interleukin 10 (IL-10) genetic profile and the expression of A2AR in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer disease (AD), and age-matched controls to verify, if they may help distinguish different forms of cognitive decline. We analyzed the IL-10 genotype and the expression of A2AR in 41 subjects with AD, 10 with amnestic MCI (a-MCI), 49 with multiple cognitive domain MCI (mcd-MCI), and 46 controls. There was a significant linear increase in A2AR mRNA levels and A2AR density from mcd-MCI to a-MCI, with intermediate levels being found in AD. The IL-10 AA genotype frequency was 67% in a-MCI, 46% in AD, 35% in mcd-MCI, and 20% in controls. These data suggest that the assessment of the IL-10 genotype and the expression of A2AR in PBMCs may be a valuable means of differentiating between a-MCI and mcd-MCI.

Download Full-text